Ken Griffin Applied Molecular Transport Inc. Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.35 - $1.26 $63,030 - $226,908	-180,086 Reduced 88.42%	23,576 $9,000
Q3 2022 Nov 14, 2022	SELL	$1.12 - $3.12 $129,811 - $361,617	-115,903 Reduced 36.27%	203,662 $198,000
Q2 2022 Aug 15, 2022	BUY	$2.76 - $7.65 $632,354 - $1.75 Million	229,114 Added 253.3%	319,565 $930,000
Q1 2022 May 16, 2022	SELL	$5.63 - $13.88 $539,810 - $1.33 Million	-95,881 Reduced 51.46%	90,451 $680,000
Q4 2021 Feb 14, 2022	BUY	$13.23 - $26.05 $176,289 - $347,116	13,325 Added 7.7%	186,332 $2.6 Million

Q3 2021 Nov 15, 2021	BUY	$25.87 - $46.61 $4.48 Million - $8.06 Million	173,007 New	173,007 $4.48 Million
Q3 2020 Nov 16, 2020	SELL	$20.49 - $33.58 $14.7 Million - $24.1 Million	-717,330 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$17.98 - $28.0 $12.9 Million - $20.1 Million	717,330 New	717,330 $18 Million

9.42K

Ticker AMTI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,900,600
Description
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of r...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.